The latest valuation work on Rapport Therapeutics lifts estimated fair value from US$62.88 to US$69.06, putting a sharper focus on how RAP-219 could shape the long term story. Analysts link this higher mark to bipolar mania data that met key endpoints, a safety profile they describe as encouraging, and the potential for broader use across epilepsy and psychiatric conditions, even as they flag execution and tolerability risks. Read on to see how to track these changing targets and follow the evolving analyst narrative around Rapport Therapeutics.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several firms, including Jones, Citizens and Raymond James, increased price targets after RAP-219 met primary and key secondary endpoints in Phase 2 bipolar mania, reflecting more optimistic modeled outcomes for Rapport Therapeutics.
-
Citizens, Guggenheim and H.C. Wainwright highlight RAP-219 as a potential pipeline in a product, with upside they link to both epilepsy and psychiatric uses based on current trial data and program design.
-
UBS and William Blair focus on RAP-219 in focal onset seizures, citing precision targeting, the planned long acting injectable and prior seizure reduction data as key supports for their views on the stock.
🐻 Bearish Takeaways
-
Wells Fargo trims its target to US$50 and flags agitation events and discontinuation rates as potential constraints on how investors value Rapport Therapeutics, even while characterizing RAP-219 as active and non sedating.
-
Raymond James points to a 3.1 point placebo adjusted YMRS benefit that fell short of investor expectations, which the firm believes has limited near term enthusiasm even after a positive readout.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for Rapport Therapeutics. See which could impact your investment.
How This Changes the Fair Value For Rapport Therapeutics
-
Fair Value moves from US$62.88 to US$69.06 based on updated inputs for Rapport Therapeutics.
-
Revenue Growth now reflects a smaller modeled decline, shifting from a 69.80% decline to a 27.34% decline.
-
Net Profit Margin adjusts from 17.11% to 17.17% in the updated assumptions.
-
Future P/E changes from a very large 40,265.64x to 3,164.21x in the revised model.
-
The Discount Rate remains essentially unchanged at 7.24%.
Never Miss an Update: Follow The Narrative
Narratives link Rapport Therapeutics' clinical and business story to an evolving financial forecast and fair value. They update automatically as new data and company news arrive, so you can see how the thesis is changing over time.
Head over to the Simply Wall St Community and follow the Narrative on Rapport Therapeutics to stay up to date on:
-
How RAP-219 in focal onset seizures and bipolar mania supports the idea of a scalable precision neuroscience platform.
-
Key potential catalysts around Phase 3 epilepsy trials, the pivotal-like Phase 2 bipolar mania study, long acting injectable work and new CNS indications such as pain and migraine.
-
Main risks that could challenge the thesis, including RAP-219 trial outcomes, cash runway pressure if milestones slip and the impact of ongoing insider and venture holder share sales.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RAPP .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
